What Should We Do with the Exceptional Responders?

Charles Ryan | February 09, 2019

I have been thinking a lot about the outliers, the exceptional responders, those rare patients for whom we have cracked the code and end up with a PSA of zero after we treat them with abiraterone, immunotherapy or other treatments - and what to do about them.

READ MORE PREVIOUS ARTICLES

Dr. Charles J. Ryan, MD

Charles J. Ryan, MD is the B.J. Kennedy Chair in Clinical Medical Oncology at the University of Minnesota and Director of the Division of Hematology, Oncology and Transplantation. He previously held the position of Professor of Clinical Medicine and Urology and the Clinical Program Leader for Genitourinary Medical Oncology at the UCSF Helen Diller Family Comprehensive Cancer Center

Videos
State-of-the-industry video lectures by leading urology experts
Conference Coverage
Recent data from conferences worldwide

ASCO GU 2019 Prostate Cancer

ESOU 2019 Prostate Cancer

SUO 2018 Prostate Cancer

ESMO 2018 Prostate Cancer

SIU 2018

ASCO 2018 Prostate Cancer

AUA 2018 Prostate Cancer

EAU 2018 Prostate Cancer

ASCO GU 2018 Prostate Cancer

SUO 2017 - Prostate Cancer

SIU 2017 Prostate Cancer

ESMO 2017 Prostate Cancer

CUA 2017

TAT-10

ASCO 2017 Prostate Cancer

AUA 2016 Prostate cancer

ASCO GU 2016 Prostate Cancer

ASCO GU 2016 mCRPC Treatment

@UroToday
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe